Parathyroid surgery may boost mobility in seniors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Age ≥ 60 years; * Biochemical diagnosis of hypercalcemic (corrected serum calcium \>10.2 mg/dL or ionized serum calcium \>1.31 mmol/dL or 5.2 mg/dL on at least one serum sample) primary hyperparathyroidism as determined by board-certified endocrinologist or endocrine surgeon; * Undergoing parathyroidectomy at UF Health; * Willing and able to give informed consent. Exclusion: * Failure to provide informed consent; * Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum calcium ≤10.2 mg/dL or ionized serum calcium ≤1.31 mmol/dL or 5.2 mg/dL on at least one serum sample); * Elected not to undergo parathyroidectomy at UF Health; * Major surgery as deemed by principal investigator or hip/knee replacement in the past 6 months; * Fractures to the hands, arms or legs within the last 6 months; * Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.) resulting in orthopedic trauma or requiring prolonged immobilization (\>2 weeks) within the last 6 months; * Blood transfusion within the past 3 months; * Self-reported myocardial infarction, cerebrovascular accident, or unstable angina within the past 6 months; * NYHA Class 3 or 4 congestive heart failure; * Major psychiatric disorder; * Cancer requiring treatment in the past 1 year (including metastatic cancer), except for locally treated non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer); * Renal failure requiring hemodialysis or peritoneal dialysis * Use of bone-modifying therapies (alendronate \[Fosamax\], zoledronic acid \[Reclast\], denosumab \[Prolia or Xgeva\], or romosozumab \[Evenity\]) within 1 month of planned surgery * Planning to permanently leave the area within 3 months of parathyroidectomy; * Vision or hearing impairment - defined as unable to read or listen/follow instructions despite the use of maximal assistive devices (i.e. contact lenses, glasses, hearing aids, etc.) * Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment.